CAJ | 학술논문

目的探讨立体定向放疗(SRT)联合EP方案化疗治疗高龄局限期小细胞肺癌的临床意义.方法 23例高龄局限期小细胞肺癌立体定向放疗联合EP方案化疗,SRT处方剂量50～60 Gy,中位剂量56 Gy.EP方案化疗:顺铂(DDP)20 mg/d,依托泊昔(VP-16)100 mg/d,均第1～5天静脉滴注,3周为1个周期,化疗2～4个周期.结果局部控制率(CR+PR)为82.5%,1、2年生存率分别为61.8%、29.0%,中位生存期为13.1个月,局部复发率19%,远处转移率为43%.结论立体定向放疗联合EP方案化疗治疗高龄局限期小细胞肺癌疗效较好,不良反应可以耐受.
목적 탐토입체정향방료(SRT)연합EP방안화료치료고령국한기소세포폐암적림상의의.방법 23례고령국한기소세포폐암입체정향방료연합EP방안화료,SRT처방제량50～60 Gy,중위제량56 Gy.EP방안화료:순박(DDP)20 mg/d,의탁박석(VP-16)100 mg/d,균제1～5천정맥적주,3주위1개주기,화료2～4개주기.결과 국부공제솔(CR+PR)위82.5%,1、2년생존솔분별위61.8%、29.0%,중위생존기위13.1개월,국부복발솔19%,원처전이솔위43%.결론 입체정향방료연합EP방안화료치료고령국한기소세포폐암료효교호,불량반응가이내수.
Objective To evaluate of stereotactic radiotherapy(SRT) combined with chemotherapy in etoposide -cisplatin for elderly limited-stage small-cell lung cancerr(LD-SCLC). Methods Twenty three cases of elderly patients with LD-SCLC were treated by SRT(prescription dose was 56 -72 Gy, with a median of 60.8 Gy) and chemotherapy (EP: cisplatin 20 mg d1-5, E: etoposide 100 mg d 1-5, three weeks for a cycle. For two to four cycles). Results The local control rate (CR + PR) was 82.5%, the 1,2 year survival rates was 67.8% and 29.0% respectively,with a median survival time 13.1 months. The frequencies was 19%, and distant metastasis was 43%. Conclusions The SRT combined with chemotherapy with etoposide-cisplatin for elderly limited-stage small-cell lung cancer could be more effectively, and the elderly patients could tolerate the side effects.